多西他赛、奥沙利铂联合卡培他滨新辅助化疗对进展期胃癌的疗效  

Therapeutic effect of neoadjuvant chemotherapy combined with docetaxel,oxaliplatin and capecitabine in the treatment of advanced gastric cancer

作　　者：王长明[1] 沈丕杰[1] 卫子然[1] 朱振新[1] 蔡清萍[1] 颜荣林[1] 

机构地区：[1]第二军医大学长征医院胃肠外科,上海200003

出　　处：《药学服务与研究》2012年第4期291-294,共4页Pharmaceutical Care and Research

摘　　要：目的:探讨多西他赛、奥沙利铂联合卡培他滨(简称DOX方案)新辅助化疗在进展期胃癌中的临床疗效及不良反应。方法:对2008-06-01至2011-05-31于第二军医大学长征医院胃肠外科就诊的186例进展期胃癌病人,应用多西他赛75mg/m2,静脉滴注,第1天;奥沙利铂130mg/m2,静脉滴注,第2天;卡培他滨1 000mg/m2,口服,bid,第1天至第14天;3周为1个疗程,共2～3个疗程,化疗结束后2～3周手术。结果:总有效率67.8%,完全缓解7例(3.8%),部分缓解119例(64.0%),手术切除率81.5%,R0切除率80.4%。主要不良反应为骨髓抑制和恶心、呕吐。结论:多西他赛、奥沙利铂联合卡培他滨方案新辅助化疗治疗进展期胃癌可以提高手术的根治性切除率,其不良反应发生率尚在可接受范围。Objective： To investigate the therapeutic effect and adverse drug reactions（ADRs） of neoadjuvant chemothera- py combined with docetaxel, oxaliplatin and capecitabine（DOX regimen） in the treatment of advanced gastric cancer. Methods： One hundred and eighty-six patients with advanced gastric cancer in Department of Gastrointestinal Surgery, Changzheng Hos- pital,Second Military Medical University from 2008 06-01 to 2011 05 31 received neoadjuvant chemotherapy. Neoadjuvant chemotherapy regimen was as follows： 75 mg/m2 docetaxel （ iv gtt, on day 1 ）, 130 mg/m2 oxaliplatin （ iv gtt, on day 2 ）, 1 000 mg/m2 capeeitabine （bid,po,on days 1 14） with 3 weeks as one treatment course,totalling 2-3 courses. And the patients received surgery,2-3 weeks after termination of chemotherapy. Results： Total response rate was 67.8%, complete response rate was 3.8%（7 patients）, partial response rate was 64.0%0（119 patients）. Total resection rate was 81.5%, R0 resection rate was 80. 4%. Main ADRs were myelosuppression, nausea and vomiting. Conclusion： Overall curative resection rate was in creased in patients with advanced gastric cancer, after neoadjuvant chemotherapy with docetaxel, oxaliplatin and capecitabine. The ADRs rate of neoadjuvant chemotherapy was within acceptable range.

关 键 词：新辅助化疗 进展期胃癌 多西他赛 奥沙利铂 卡培他滨 

分 类 号：R735.2[医药卫生—肿瘤]